ENFORTUMAB VEDOTIN , mRNA-4157, Placebo to V940, KEYTRUDA 25 mg/mL concentrate for solution for infusion
V940-005
Phase 2 small_molecule active
Quick answer
ENFORTUMAB VEDOTIN , mRNA-4157, Placebo to V940, KEYTRUDA 25 mg/mL concentrate for solution for infusion for Muscle-invasive Urothelial Carcinoma is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Muscle-invasive Urothelial Carcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active